These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 32933754)

  • 1. REDUCE-IT Eligibility and Preventable Cardiovascular Events in the US Population (from the National Health and Nutrition Examination Survey [NHANES]).
    Wong ND; Fan W; Philip S; Granowitz C; Toth PP
    Am J Cardiol; 2020 Nov; 134():62-68. PubMed ID: 32933754
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LEADER Trial Eligibility and Preventable Cardiovascular Events in US Adults with Diabetes: the National Health and Nutrition Examination Surveys 2007-2016.
    Fan W; Tong C; Wong ND
    Cardiovasc Drugs Ther; 2020 Dec; 34(6):737-743. PubMed ID: 32621045
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative Reductions in Investigator-Reported and Adjudicated Ischemic Events in REDUCE-IT.
    Gaba P; Bhatt DL; Giugliano RP; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Ballantyne CM; Pinto DS; Budoff MJ; Gibson CM
    J Am Coll Cardiol; 2021 Oct; 78(15):1525-1537. PubMed ID: 34620410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl.
    Derington CG; Bress AP; Herrick JS; Fan W; Wong ND; Andrade KE; Johnson J; Philip S; Abrahamson D; Jiao L; Bhatt DL; Weintraub WS
    Am J Prev Cardiol; 2022 Jun; 10():100345. PubMed ID: 35574517
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The case for adding eicosapentaenoic acid (icosapent ethyl) to the ABCs of cardiovascular disease prevention.
    Trivedi K; Le V; Nelson JR
    Postgrad Med; 2021 Jan; 133(1):28-41. PubMed ID: 32762268
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Benefits of Icosapent Ethyl Across the Range of Kidney Function in Patients With Established Cardiovascular Disease or Diabetes: REDUCE-IT RENAL.
    Majithia A; Bhatt DL; Friedman AN; Miller M; Steg PG; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Budoff M; Preston Mason R; Tardif JC; Boden WE; Ballantyne CM
    Circulation; 2021 Nov; 144(22):1750-1759. PubMed ID: 34706555
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Ballantyne CM;
    N Engl J Med; 2019 Jan; 380(1):11-22. PubMed ID: 30415628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rationale and design of REDUCE-IT: Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial.
    Bhatt DL; Steg PG; Brinton EA; Jacobson TA; Miller M; Tardif JC; Ketchum SB; Doyle RT; Murphy SA; Soni PN; Braeckman RA; Juliano RA; Ballantyne CM;
    Clin Cardiol; 2017 Mar; 40(3):138-148. PubMed ID: 28294373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Icosapent ethyl: drug profile and evidence of reduced residual cardiovascular risk in patients with statin-managed LDL-C cholesterol.
    Bazarbashi N; Miller M
    Expert Rev Cardiovasc Ther; 2020 Apr; 18(4):175-180. PubMed ID: 32228246
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Icosapent Ethyl for Primary Versus Secondary Prevention of Major Adverse Cardiovascular Events in Hypertriglyceridemia: Value for Money Analysis.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Med; 2021 Jul; 134(7):e415-e419. PubMed ID: 33450273
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Icosapent Ethyl on Total Ischemic Events: From REDUCE-IT.
    Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Doyle RT; Juliano RA; Jiao L; Granowitz C; Tardif JC; Gregson J; Pocock SJ; Ballantyne CM;
    J Am Coll Cardiol; 2019 Jun; 73(22):2791-2802. PubMed ID: 30898607
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevention of Cardiovascular Events and Mortality With Icosapent Ethyl in Patients With Prior Myocardial Infarction.
    Gaba P; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Tardif JC; Giugliano RP; Martens FMAC; Gibson CM; Ballantyne CM;
    J Am Coll Cardiol; 2022 May; 79(17):1660-1671. PubMed ID: 35483753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. National Lipid Association Scientific Statement on the use of icosapent ethyl in statin-treated patients with elevated triglycerides and high or very-high ASCVD risk.
    Orringer CE; Jacobson TA; Maki KC
    J Clin Lipidol; 2019; 13(6):860-872. PubMed ID: 31787586
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Icosapent ethyl for reduction of persistent cardiovascular risk: a critical review of major medical society guidelines and statements.
    Miller M; Tokgozoglu L; Parhofer KG; Handelsman Y; Leiter LA; Landmesser U; Brinton EA; Catapano AL
    Expert Rev Cardiovasc Ther; 2022 Aug; 20(8):609-625. PubMed ID: 35876118
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of icosapent ethyl according to baseline residual risk in patients with atherosclerotic cardiovascular disease: results from REDUCE-IT.
    Burger PM; Bhatt DL; Dorresteijn JAN; Koudstaal S; Mosterd A; Martens FMAC; Steg PG; Visseren FLJ;
    Eur Heart J Cardiovasc Pharmacother; 2024 Oct; 10(6):488-499. PubMed ID: 38678009
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduction in Revascularization With Icosapent Ethyl: Insights From REDUCE-IT Revascularization Analyses.
    Peterson BE; Bhatt DL; Steg PG; Miller M; Brinton EA; Jacobson TA; Ketchum SB; Juliano RA; Jiao L; Doyle RT; Granowitz C; Gibson CM; Pinto D; Giugliano RP; Budoff MJ; Tardif JC; Verma S; Ballantyne CM;
    Circulation; 2021 Jan; 143(1):33-44. PubMed ID: 33148016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The cost-effectiveness of omega-3 polyunsaturated fatty acids - The Australian healthcare perspective.
    Gao L; Moodie M; Li SC
    Eur J Intern Med; 2019 Sep; 67():70-76. PubMed ID: 31285124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Icosapent ethyl for dyslipidaemia in patients with diabetes and coronary artery disease: Act now to reduce it.
    Lan NSR; Fegan PG; Yeap BB; Rankin JM; Watts GF
    Diabetes Obes Metab; 2019 Jul; 21(7):1734-1736. PubMed ID: 30834678
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipid Effects of Icosapent Ethyl in Women with Diabetes Mellitus and Persistent High Triglycerides on Statin Treatment: ANCHOR Trial Subanalysis.
    Brinton EA; Ballantyne CM; Guyton JR; Philip S; Doyle RT; Juliano RA; Mosca L
    J Womens Health (Larchmt); 2018 Sep; 27(9):1170-1176. PubMed ID: 29583081
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Catch of the Day: Icosapent Ethyl for Reducing Cardiovascular Risk.
    Dixon DL
    Am J Med; 2020 Jul; 133(7):802-804. PubMed ID: 32243872
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.